|
Clemastine Fumarate Clinical Trials
3 actively recruiting trials across 3 locations
▲ +1 trial since June 2026
Also known as: Clemastine, Dayhist, Dayhist Allergy, Tavegyl, Tavist Allergy +1 more
Pipeline
Phase 2: 1Phase 1/2: 2
Top Sponsors
- University of Illinois at Chicago1
- University of California, San Francisco1
- National Institute of Allergy and Infectious Diseases (NIAID)1
Indications
- Multiple Sclerosis2
- Multiple Sclerosis Benign1
- Multiple Sclerosis Brain Lesion1
- Multiple Sclerosis Relapse1
- Multiple Sclerosis, Chronic Progressive1
San Francisco, California1 trial
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Sandler Neurosciences Building, Neurological Clinical Research Unit
Phase 1/2
Chicago, Illinois1 trial
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
University of Illinois College of Medicine
Phase 2
Bethesda, Maryland1 trial
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
National Institutes of Health Clinical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.